Abbonarsi

Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease - 05/02/15

Doi : 10.1016/j.jaci.2014.07.022 
John Croese, MD a, b, , Paul Giacomin, PhD b, , Severine Navarro, PhD b, Andrew Clouston, MD c, Leisa McCann, RN b, Annette Dougall, PhD b, Ivana Ferreira, BSc b, Atik Susianto, MD b, Peter O'Rourke, PhD d, Mariko Howlett, MD e, James McCarthy, MD d, e, Christian Engwerda, PhD d, Dianne Jones, BHSc f, Alex Loukas, PhD b,
a Department of Gastroenterology and Hepatology, The Prince Charles Hospital, Brisbane, Australia 
b Center for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia 
c Envoi Specialist Pathologists, Brisbane, Australia 
d QIMR Berghofer Medical Research Institute, Brisbane, Australia 
e Royal Brisbane and Women's Hospital, Brisbane, Australia 
f Logan Hospital, Brisbane, Australia 

Corresponding authors: John Croese, MD, Gastroenterology Unit, The Prince Charles Hospital, Rode Rd, Chermside, Brisbane, QLD 4032, Australia.∗∗Alex Loukas, PhD, Australian Institute of Tropical Health & Medicine, James Cook University, McGregor Rd, Smithfield, Cairns, QLD 4878, Australia.

Abstract

Background

Celiac disease (CeD) is a common gluten-sensitive autoimmune enteropathy. A gluten-free diet is an effective treatment, but compliance is demanding; hence, new treatment strategies for CeD are required.

Objective

Parasitic helminths hold promise for treating inflammatory disorders, so we examined the influence of experimental hookworm infection on the predicted outcomes of escalating gluten challenges in CeD subjects.

Methods

A 52-week study was conducted involving 12 adults with diet-managed CeD. Subjects were inoculated with 20 Necator americanus larvae, and escalating gluten challenges consumed as pasta were subsequently administered: (1) 10 to 50 mg for 12 weeks (microchallenge); (2) 25 mg daily + 1 g twice weekly for 12 weeks (GC-1g); and (3) 3 g daily (60-75 straws of spaghetti) for 2 weeks (GC-3g). Symptomatic, serologic, and histological outcomes evaluated gluten toxicity. Regulatory and inflammatory T cell populations in blood and mucosa were examined.

Results

Two gluten-intolerant subjects were withdrawn after microchallenge. Ten completed GC-1g, 8 of whom enrolled in and completed GC-3g. Primary outcomes: median villous height-to-crypt depth ratios (2.60-2.63; P = .98) did not decrease as predicted after GC-1g, and the mean IgA-tissue transglutaminase titers declined, contrary to the predicted rise after GC-3g. Secondary outcomes: quality of life scores improved (46.3-40.6; P = .05); celiac symptom indices (24.3-24.3; P = .53), intra-epithelial lymphocyte percentages (32.5-35.0; P = .47), and Marsh scores were unchanged by gluten challenge. Intestinal T cells expressing IFNγ were reduced following hookworm infection (23.9%-11.5%; P = .04), with corresponding increases in CD4+ Foxp3+ regulatory T cells (0.19%-1.12%; P = .001).

Conclusions

Necator americanus and gluten microchallenge promoted tolerance and stabilized or improved all tested indices of gluten toxicity in CeD subjects.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Celiac disease, gluten, hookworm, autoimmunity, helminth therapy, desensitization, mucosal immunology, regulatory T cells, intra-epithelial lymphocytes

Abbreviations used : CeD, CSI, DG, GC, GFD, IEL, LPL, NA, Treg, QOL, tTG, Vh:Cd


Mappa


 The work was funded by an Australian National Health and Medical Research Council (NHMRC) Program Grant (1037304 to A.L., C.E., and J.M.), NHMRC Overseas Biomedical Fellowship 613718 (to P.G.), NHMRC Principal Research Fellowship (1020114 to A.L.), NHMRC Senior Research Fellowship (1058685 to C.E.), NHMRC Practitioner Fellowship and Government of Queensland Health Research Fellowship (1041802 to J.M.) and a Far North Queensland Hospital Foundation Small Research Grant (P.G. and S.N.).
 Disclosure of potential conflict of interest: This work was funded by an Australian National Health and Medical Research Council Program Grant (1037304). The authors declare that they have no other relevant conflicts of interest.


© 2014  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 135 - N° 2

P. 508 - febbraio 2015 Ritorno al numero
Articolo precedente Articolo precedente
  • Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis
  • Marc E. Rothenberg, Ting Wen, Allison Greenberg, Oral Alpan, Benjamin Enav, Ikuo Hirano, Kari Nadeau, Sergio Kaiser, Thomas Peters, Antonio Perez, Ieuan Jones, Jonathan P. Arm, Robert M. Strieter, Ronald Sabo, Kulasiri A. Gunawardena
| Articolo seguente Articolo seguente
  • Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease
  • Ruby F. Fernandez-Boyanapalli, S. Courtney Frasch, Stacey M. Thomas, Kenneth C. Malcolm, Michael Nicks, Ronald J. Harbeck, Claudia V. Jakubzick, Raphael Nemenoff, Peter M. Henson, Steven M. Holland, Donna L. Bratton

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.